DOCSLIB.ORG

Wo 2010/127231 A2

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 4 November 2010 (04.11.2010) WO 2010/127231 A2 (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every AOlN 33/12 (2006.01) A61K 31/14 (2006.01) kind of national protection available): AE, AG, AL, AM, AOlN 25/04 (2006.01) CIlD 3/26 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, AOlP 1/00 (2006.01) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, PCT/US2010/033 148 KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, (22) International Filing Date: ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, 30 April 2010 (30.04.2010) NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, (25) Filing Language: English TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 61/174,724 1 May 2009 (01 .05.2009) US GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, (71) Applicant (for all designated States except US): SIG¬ TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, NAL INVESTMENT AND MANAGEMENT CO. ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, [US/US]; 1105 N. Market Street, Suite 1300, Wilming MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, ton, DE 19801 (US). TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG). (72) Inventors; and (75) Inventors/ Applicants (for US only): SONDGEROTH, Published: Jason [US/US]; 7008 Flagstone Drive, Ooltewah, TN — without international search report and to be republished 37363 (US). CZERWINKSKI, Joe [US/US]; 172 Brock upon receipt of that report (Rule 48.2(g)) Creek, Signal Mt, TN 37377 (US). (74) Agents: DICKEY, Lara, S. et al; Husfch Blackwell Sanders LLP, 4801 Main Street, Suite 1000, Kansas City, MO 641 12-255 1 (US). (54) Title: MOISTURIZING ANTIMICROBIAL COMPOSITION (57) Abstract: An antimicrobial moisturizing composition includes benzethonium chloride or benzalkonium chloride, a non-ben- zyl cationic surfactant, and an aqueous carrier. The composition of the present invention provides a significant and unexpected re- duction of irritation, inflammation, dryness and/or redness, all issues associated with known alcohol- based skin disinfectants. In particular, the present invention provides a stable, aesthetically- pleasing, long-lasting, and moisturizing antimicrobial composi- tion that is substantially free of ethanol, polysorbates, and anionic compounds that are known to inhibit the activity of benzethoni- um chloride or benzalkonium chloride. MOISTURIZING ANTIMICROBIAL COMPOSITION BACKGROUND ART A significant cause of many illnesses has long been known to involve the transmission through skin contact of bacteria, germs, microorganisms, viruses and other deleterious substances. From sniffing coworkers to raw chicken on a kitchen cutting board, every day life is full of potential infectious disease hazards. Infectious diseases typically spread through two types of contact. With direct contact, infectious disease can be spread in three different ways. The most common way for infectious disease to spread is through the direct transfer of bacteria, viruses or other germs from one person to another. This can occur when an individual with the bacterium or virus touches or coughs on someone who is not infected. These germs can also spread through the exchange of body fluids from sexual contact or a blood transfusion. Many household pets also carry a variety of germs. Being bitten or scratched by an infected animal can make a person sick and, in extreme circumstances, could even cause death. Handling animal waste can be hazardous, too. In a third type of direct contact, a pregnant woman may pass germs that cause infectious diseases to her unborn baby. Germs can pass through the placenta, as is the case of the AIDS virus and the toxoplasmosis parasite. Or germs could spread during labor and delivery, as is the case for a mother infected with group B streptococcus. Disease-causing organisms can also be passed along by indirect contact. Many germs can linger on an inanimate object, such as a tabletop, doorknob or faucet handle. When a person touches the same doorknob grasped by someone ill with the flu or a cold, for example, it is possible to pick up the germs the infected person left behind. By subsequently touching one's eyes, mouth or nose, the uninfected person may become infected. Some infections occur from organisms that naturally live in the environment but are not passed from person to person. Examples include fungal infections like histoplasmosis or blastomycosis, as well as bacterial infections such as anthrax. Infectious diseases can also spread through the air. For example, when a person coughs or sneezes, droplets are expelled into the air. When that person is sick with a cold or the flu — or any number of other illnesses — these droplets contain the germ-causing illness. Spread of infectious disease in this manner is called droplet spread or droplet transmission. Droplets travel only about three feet because they're usually too large to stay suspended in the air for a long time. However, if a droplet from an infected person comes in contact with your eyes, nose or mouth, you may soon experience symptoms of the illness. Crowded, indoor environments may promote the chances of droplet transmission — which may explain the increase in respiratory infections in the winter months. Some disease-causing germs travel through the air in particles considerably smaller than droplets. These tiny particles remain suspended in the air for extended periods of time and can travel in air currents. If you breathe in an airborne virus, bacterium or other germ, you may become infected and show signs and symptoms of the disease. Colds caused by viruses, influenza and tuberculosis are a few types of infectious diseases usually spread through the air, in both particle and droplet forms. Some germs rely on insect carriers — such as mosquitoes, fleas, lice or ticks — to move from host to host. These carriers are known as vectors. Mosquitoes can carry the malaria parasite or West Nile virus, and deer ticks may carry the bacterium that causes Lyme disease. The vector-borne spread of germs happens when an insect that carries the germ on its body or in its intestinal tract lands on you or bites you. The germs move into your body and can make you sick. Sometimes the germs that cause infectious disease need the insect for specific biological reasons. They use the insect's body to multiply, which is necessary before the germs can infect a new host. Another way disease-causing germs can infect you is through contaminated food and water. Sometimes called common-vehicle transmission, this mechanism of transmission allows germs to be spread to many people through a single source. Food is often the vehicle that spreads the germs and causes the illness. For instance, contamination with Escherichia coli (E. coli) is common. E. coli is a bacterium present in or on certain foods — such as undercooked hamburger or unwashed fruits or vegetables. When you eat foods contaminated with E. coli, chances are you'll experience an illness — sometimes referred to as food poisoning. According to many experts, including the Centers for Disease Control, hand washing is the single most effective way to prevent the spread of infectious diseases. However, when the convenience of soap and water is not readily available, hand washing may not be an option. Skin disinfectants that do not require the application of water have therefore been developed in response to the need for a skin disinfectant that is effective and easy to use. However, many of these skin disinfectants use alcohol as the primary antimicrobial agent. This is problematic because the effective concentration of alcohol, especially ethanol, generally believed to about greater than about 60% by weight, is irritating to the skin and can cause dryness with resultant peeling and cracking. Because chapped skin tends to be more susceptible to microbial contamination, repeated use of alcohol disinfectants can exacerbate the very problem they are intended to solve. Benzethonium chloride has also been used in known skin disinfectants. However, the antimicrobial activity of benzethonium chloride is easily inhibited by polysorbates and anionics that are commonly used in skin disinfectant formulations. There is therefore a need in the art for an antimicrobial composition that is effective as a skin disinfectant but does not cause increased irritation to the skin of the average user. DISCLOSURE OF INVENTION In one of many illustrative aspects of the present invention, there is provided an improved antimicrobial moisturizing composition, the improved composition including purified water, benzethonium chloride or benzalkonium chloride, and a cationic surfactant. In another illustrative aspect of the present invention there is provided a method of making the improved composition of the present invention. In yet another illustrative aspect of the present invention there is provided a method of topically administering to an affected area a non-toxic effective dosage of the improved composition. BEST MODE FOR CARRYING OUT THE INVENTION The present invention is generally directed to a moisturizing antimicrobial composition and its use.
Recommended publications
  • Quaternary Ammonium Compounds

    Quaternary Ammonium Compounds

    FACT SHEET: Quaternary Ammonium Compounds Quaternary ammonium compounds, also known as “quats” or “QACs,” include a number of chemicals used as sanitizers and disinfectants, including benzalkonium chloride, benzethonium chloride, cetalkonium chloride, cetrimide, cetrimonium bromide, cetylpyridinium chloride, glycidyl trimethyl, ammonium chloride, and stearalkonium chloride.[i] In general, quats cause toxic effects through all Mutagenicity routes of exposure including inhalation, Some quats have shown to be mutagenic and to ingestion, dermal application, and irrigation of damage animal DNA and DNA in human body cavities. Exposure to diluted solutions may lymphocytes at much lower levels than are result in mild irritation, while concentrated present in cleaning chemicals.[6] solutions are corrosive, causing burns to the skin and mucous Membranes. They can produce Antimicrobial Resistance systemic toxicity and can also cause allergic Genes have been discovered that mediate reactions.[2] resistance to quats. There has been an association of some of these genes with beta lactamase genes, Asthma and Allergies raising concern for a relationship between Of particular interest with regard to use as disinfectant resistance and antibiotic resistance.[7] disinfectants in the COVID-19 pandemic, quats increase the risk for asthma and allergic Reproductive Toxicity sensitization. Evidence from occupational Mice whose cages were cleaned with QACs had exposures shows increased risk of rhinitis and very low fertility rates. [8] Exposure to a common asthma
  • FDA-2015-N-0101; and FDA-2016-N-0124

    FDA-2015-N-0101; and FDA-2016-N-0124

    DE PARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Silver Spring MD 20993 November 18, 2020 Docket Nos. FDA-1975-N-0012; FDA-2015-N-0101; and FDA-2016-N-0124 The American Cleaning Institute Attention: James Kim, PhD Vice President, Science and Regulatory Affairs 1401 H Street, N.W. Suite 700 Washington, D.C. 20005 Re: Benzalkonium Chloride, Benzethonium Chloride, Chloroxylenol, Ethanol, and Povidone-Iodine Dear Dr. Kim: This letter responds to The American Cleaning Institute’s (ACI’s) July 14, 2020 communication regarding the deferral from final rulemaking under the over-the-counter (OTC) Drug Review on benzalkonium chloride, benzethonium chloride, chloroxylenol, ethanol, and povidone-iodine for use in nonprescription (often referred to as over-the-counter or OTC) consumer antiseptic wash, health care antiseptic, and consumer antiseptic rub drug products. In March 2016, FDA issued letters granting requests to defer three active ingredients— benzalkonium chloride, benzethonium chloride, and chloroxylenol—from inclusion in the final rulemaking for the December 2013 proposed rule for OTC consumer antiseptic washes (78 FR 76444). Similarly, in January 2017, FDA issued letters granting requests to defer six active ingredients—benzalkonium chloride, benzethonium chloride, chloroxylenol, ethanol, povidone- iodine, and isopropyl alcohol—from inclusion in the final rulemaking for the May 2015 proposed rule for OTC health care antiseptics (80 FR 25166). In October 2017, FDA issued letters granting requests to defer three active
  • A Screening-Based Approach to Circumvent Tumor Microenvironment

    A Screening-Based Approach to Circumvent Tumor Microenvironment

    JBXXXX10.1177/1087057113501081Journal of Biomolecular ScreeningSingh et al. 501081research-article2013 Original Research Journal of Biomolecular Screening 2014, Vol 19(1) 158 –167 A Screening-Based Approach to © 2013 Society for Laboratory Automation and Screening DOI: 10.1177/1087057113501081 Circumvent Tumor Microenvironment- jbx.sagepub.com Driven Intrinsic Resistance to BCR-ABL+ Inhibitors in Ph+ Acute Lymphoblastic Leukemia Harpreet Singh1,2, Anang A. Shelat3, Amandeep Singh4, Nidal Boulos1, Richard T. Williams1,2*, and R. Kiplin Guy2,3 Abstract Signaling by the BCR-ABL fusion kinase drives Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL) and chronic myelogenous leukemia (CML). Despite their clinical activity in many patients with CML, the BCR-ABL kinase inhibitors (BCR-ABL-KIs) imatinib, dasatinib, and nilotinib provide only transient leukemia reduction in patients with Ph+ ALL. While host-derived growth factors in the leukemia microenvironment have been invoked to explain this drug resistance, their relative contribution remains uncertain. Using genetically defined murine Ph+ ALL cells, we identified interleukin 7 (IL-7) as the dominant host factor that attenuates response to BCR-ABL-KIs. To identify potential combination drugs that could overcome this IL-7–dependent BCR-ABL-KI–resistant phenotype, we screened a small-molecule library including Food and Drug Administration–approved drugs. Among the validated hits, the well-tolerated antimalarial drug dihydroartemisinin (DHA) displayed potent activity in vitro and modest in vivo monotherapy activity against engineered murine BCR-ABL-KI–resistant Ph+ ALL. Strikingly, cotreatment with DHA and dasatinib in vivo strongly reduced primary leukemia burden and improved long-term survival in a murine model that faithfully captures the BCR-ABL-KI–resistant phenotype of human Ph+ ALL.
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set

    Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set

    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
  • Toxicological Evaluation Purifog.Pdf

    Toxicological Evaluation Purifog.Pdf

    Università degli Studi di Torino Prof Valter Maurino Dipartimento di Chimica phone: +39 0116705218 fax: +39 0116707615 Via P. Giuria, 7 10125 Torino Italy e-mail: [email protected] Toxicological evaluation of “PURIFOG” Page 2/24 Short term/single exposure .................................................................................................................................... 17 Inhalation ............................................................................................................................................................... 17 Oral administration LD50 ..................................................................................................................................... 17 Dermal application LD50 ...................................................................................................................................... 18 Skin irritation ........................................................................................................................................................ 18 Sensitisation .......................................................................................................................................................... 18 Mucous membranes and eye ................................................................................................................................ 18 LD and LC50 reported values for Benzyldimethyldecylammonium chloride ................................................... 19 LD and LC50 reported values for Dimethyldioctadecylammonium
  • Alcohol Based Anti-Microbial Compositions with Cosmetic Appearance

    Alcohol Based Anti-Microbial Compositions with Cosmetic Appearance

    Patentamt Europaisches ||| || 1 1| || || || 1 1| || || || || 1 1| (19) J European Patent Office Office europeen des brevets (11) EP 0 930 065 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51 ) |nt. CI.6: A61 K 7/48, A61 K 7/50, 21.07.1999 Bulletin 1999/29 ^61 |_ 2/Q0 (21) Application number: 99300394.6 (22) Date of filing : 20.01 .1 999 (84) Designated Contracting States: (72) Inventors: AT BE CH CY DE DK ES Fl FR GB GR IE IT LI LU • Jampani, Hanuman J. MC NL PT SE Grapevine, TX 76051 (US) Designated Extension States: • Newman, Jerry L. AL LT LV MK RO SI Arlington, TX 7601 6 (US) • Newman, Anthony W. (30) Priority: 20.01.1998 US 9491 Fort Worth, TX 761 1 1 (US) (71) Applicant: ETHICON INC. (74) Representative: Somerville New Jersey 08876 (US) Mercer, Christopher Paul et al Carpmaels & Ransford 43, Bloomsbury Square London WC1 A 2RA(GB) (54) Alcohol based anti-microbial compositions with cosmetic appearance (57) The present invention provides antimicrobial compositions containing high levels of alcohol, car- bomer polymers and antimicrobial agents. The present invention provides stable, high viscosity antimicrobial formulations possessing cosmetic characteristics. CM < LO CO o o CO o Q_ LU Printed by Xerox (UK) Business Services 2.16.7/3.6 EP 0 930 065 A2 Description [0001] This application is related to European patent application No. (claiming priority from USSN 09/009 489 - Attorney's ref: P020733EP) and European patent application No. (claiming 5 priority from USSN 09 -Attorney's ref: ) the disclosures of which are incorporated herein by reference.
  • Toxicological Evaluation and Limit Values for 2-Ethylhexyl Acryate, Propylene Carbonate, Quaternary Ammonium Compounds, Triglyci

    Toxicological Evaluation and Limit Values for 2-Ethylhexyl Acryate, Propylene Carbonate, Quaternary Ammonium Compounds, Triglyci

    Environmental Project No. 555 2000 Miljøprojekt Toxicological Evaluation and Limit Values for 2-Ethylhexyl acryate, Propylene carbonate, Quaternary ammonium compounds, triglycidyl isocyanurate and tripropyleneglycol diacrylate Pia Berthelsen, Vibe Beltoft, Inger Thorup, Inge Søborg and Elsa Nielsen The Institute of Food Safety and Toxicology Danish Veterinary and Food Administration The Danish Environmental Protection Agency will, when opportunity offers, publish reports and contributions relating to environmental research and development projects financed via the Danish EPA. Please note that publication does not signify that the contents of the reports necessarily reflect the views of the Danish EPA. The reports are, however, published because the Danish EPA finds that the studies represent a valuable contribution to the debate on environmental policy in Denmark. Contents Preface 5 Principles for setting of limit values for chemical substances 7 2-Ethylhexyl acrylate 11 Propylene carbonate 35 Quaternary ammonium compounds 51 Triglycidyl isocyanurate 81 Tripropyleneglycol diacrylate 111 3 4 Preface This series of reports constitutes a part of the work related to the setting of health based limit values for chemical substances in air, soil and drinking water. In this report, the toxicological documentation for the setting of limit values for 2-ethylhexyl acrylate, propylene carbonate, quaternary ammo- nium compounds, triglycidyl isocyanurate, and tripropyleneglycol diac- rylate are presented. For every substance, the following items are
  • Benefits of Benzalkonium Chloride Based Hand Sanitizers

    Benefits of Benzalkonium Chloride Based Hand Sanitizers

    Benzalkonium chloride-based Hand Sanitizers have distinct advantages over gelled alcohol hand sanitizers. While both product forms are FDA Monograph compliant for leave on products, fast acting and allow for use without water or towels, benzalkonium chloride-based products are non-flammable, less drying to skin, and will not stain clothing. Published studies report that benzalkonium chloride based hand sanitizers demonstrated greater sustained degerming activity than gelled alcohol gel hand sanitizers that actually became less effective with repeated use and made the skin dirtier, not cleaner due to removal of protective natural skin oils and entrapment of dead skin cells by the polymer thickeners used in the gelled alcohol products (AORN Journal, (68 August 1998), p. 239-251). Benzalkonium chloride, unlike benzethonium chloride, is the only quat active ingredient with a history of use in leave-on, FDA Monograph anti-bacterial skin treatment products. Leave-on Hand Sanitizers should not be used as a substitute for proper hand washing and hygiene practices. Patented Non-Alcohol Instant Foaming Hand Sanitizer produces a fast drying, non-sticky foam that contains unique non-drying, conditioning and moisturizing ingredients, leaves the skin with a soft, refreshing and silky after feel, and does not contain polymer thickeners or silicones. Multiple Instant Foam Hand Sanitizer, based on the active ingredient Benzalkonium chloride, featuring exceptional skin feel, conditioning and moisturizing properties. The efficacy of these product have been confirmed to reduce S. aureus 99.9999% in as little as 15 seconds. All of the Instant Foam Hand Sanitizer are in compliance with the FDA Final Tentative Monograph for OTC Hand Sanitizer preparations (leave-on sanitizers not requiring a rinse), and most are registered in Canada.
  • Comparative Study of Bactericidal Activities of Six Different Disinfectants

    Comparative Study of Bactericidal Activities of Six Different Disinfectants

    Nagoya J. Mod. Sci. 47. 101 ~ 112. 1985 COMPARATIVE STUDY OF BACTERICIDAL ACTIVITIES OF SIX DIFFERENT DISINFECTANTS YOSHIMICHI NAMBA*, ASAKATSU SUZUKI*, NOBORU TAKESHIMA** and NOBUO KATO*** * Department of Surgical Center, Nagoya Universi/y Hospital, and ** Deparlment of Anes/hesiology and *** Depar/ment of BaCieriology, Nagoya Universi/y School of Medicine Nagoya 466, Japan ABSTRACT Bactericidal activities of six commonly used disinfectants against scven different species of clinically isolatcd hacteria, mainly glucose-nonfermentative Gram-negative hacilli, were compared. In terms of mean values of the minimum hactericidal concentration (M BC), henzethonium chloride showed the highest efficacy, followed in order hy chlorhexidine gluconate, alkyldiaminoethylglycine hydrochloride, glutaraldehyde, povidone-iodine, and phenol. However, mean MBCs of henzethonium chloride, alkyldiaminoethylglycine hydrochloride and chlorhexidine gluconate against individual species covered a far wider range from species to species compared with those of the other three disinfectants. In addition, hactericidal activities of the ahove-mentioned three disinfectants against Pseudomonas cepacia and Achrolllohaetcr xrlosoxidans ranged more widely from strain to strain than against other species. When the minimum concentrations of individual disinfectants recommended for hospital use hy the manufacturers were used, chlorhexidine gluconate (0.02%), alkyldiaminoethylglycine hydrochloride (0.1%), henzethonium chloride (0.1%) and povidone-iodine (0.75%) were not hactericidal to definite numhers of hacterial strains tested. Among them, chlorhexidine gluconate at the concentration recommended was ineffective against many strains of all hacterial species tested, especially against strains of glucose-nonfermentative Gram-negative hacilli except for PseW/O/llOllaS aerugillosa. Alkyldiamino­ ethylglycine hydrochloride was also remarkahly ineffective against Staphylococcus aI/reus and P. cepacia. Among all the species tested, P.
  • Toxicological Evaluation of “PURIFOG Hypo” Page 1/30 Spett.Le FONDERIA MESTIERI Via Almese, 72 - 10093 Collegno (TO) - IT Tel

    Toxicological Evaluation of “PURIFOG Hypo” Page 1/30 Spett.Le FONDERIA MESTIERI Via Almese, 72 - 10093 Collegno (TO) - IT Tel

    Università degli Studi di Torino Prof Valter Maurino Dipartimento di Chimica phone: +39 0116705218 fax: +39 0116707615 Via P. Giuria, 7 10125 Torino Italy e-mail: [email protected] Toxicological evaluation of “PURIFOG Hypo” Page 1/30 Spett.le FONDERIA MESTIERI via Almese, 72 - 10093 Collegno (TO) - IT Tel. +393355977772 / +393494388929 [email protected] Toxicological evaluation of “PURIFOG Hypo” INDEX EXECUTIVE SUMMARY ....................................................................................................................................... 3 PRODUCT TO BE EVALUATED ........................................................................................................................ 3 TOXICOLOGICAL EVALUATION OF “PURIFOG HYPO” ......................................................................... 3 DIPROPYLENE GLYCOL (CAS# 25265-71-8) ........................................................................................................ 4 2, TOXICITY SUMMARY .......................................................................................................................................... 4 3 SKIN IRRITATING AND SENSITIZING EFFECTS ....................................................................................................... 5 3 REPRODUCTIVE AND DEVELOPMENTAL TOXICOLOGY ......................................................................................... 5 3 SKIN, EYE, AND RESPIRATORY IRRITATIONS .......................................................................................................
  • Pharmacy Data Management Drug Exception List

    Pharmacy Data Management Drug Exception List

    Pharmacy Data Management Drug Exception List Patch PSS*1*127 updated the following drugs with the listed NCPDP Multiplier and NCPDP Dispense Unit. These two fields were added as part of this patch to the DRUG file (#50). Please refer to the Release notes for ePharmacy/ECME Enhancements for Pharmacy Release Notes (BPS_1_5_EPHARMACY_RN_0907.PDF) on the VistA Documentation Library (VDL). The IEN column reflects the IEN for the VA PRODUCT file (#50.68). The ePharmacy Change Control Board provided the following list of drugs with the specified NCPDP Multiplier and NCPDP Dispense Unit values. This listing was used to update the DRUG file (#50) with a post install routine in the PSS*1*127 patch. NCPDP File 50.68 NCPDP Dispense IEN Product Name Multiplier Unit 2 ATROPINE SO4 0.4MG/ML INJ 1.00 ML 3 ATROPINE SO4 1% OINT,OPH 3.50 GM 6 ATROPINE SO4 1% SOLN,OPH 1.00 ML 7 ATROPINE SO4 0.5% OINT,OPH 3.50 GM 8 ATROPINE SO4 0.5% SOLN,OPH 1.00 ML 9 ATROPINE SO4 3% SOLN,OPH 1.00 ML 10 ATROPINE SO4 2% SOLN,OPH 1.00 ML 11 ATROPINE SO4 0.1MG/ML INJ 1.00 ML 12 ATROPINE SO4 0.05MG/ML INJ 1.00 ML 13 ATROPINE SO4 0.4MG/0.5ML INJ 1.00 ML 14 ATROPINE SO4 0.5MG/ML INJ 1.00 ML 15 ATROPINE SO4 1MG/ML INJ 1.00 ML 16 ATROPINE SO4 2MG/ML INJ 1.00 ML 18 ATROPINE SO4 2MG/0.7ML INJ 0.70 ML 21 ATROPINE SO4 0.3MG/ML INJ 1.00 ML 22 ATROPINE SO4 0.8MG/ML INJ 1.00 ML 23 ATROPINE SO4 0.1MG/ML INJ,SYRINGE,5ML 5.00 ML 24 ATROPINE SO4 0.1MG/ML INJ,SYRINGE,10ML 10.00 ML 25 ATROPINE SO4 1MG/ML INJ,AMP,1ML 1.00 ML 26 ATROPINE SO4 0.2MG/0.5ML INJ,AMP,0.5ML 0.50 ML 30 CODEINE PO4 30MG/ML
  • Assessment of Spermicides by a Stripping Technique Against Human

    Assessment of Spermicides by a Stripping Technique Against Human

    Assessment of spermicides by a stripping technique against human spermatozoa Janet Brotherton Department of Gynaecological Endocrinology, Sterility and Family Planning, Klinikum Steglitz of the Free University Berlin, Hindenburgdamm 30,1000 Berlin 45, Germany Summary. Fifty-two (52) compounds were tested for spermicidal activity by titration against human spermatozoa. The gradual decrease in mean sperm size was measured against increasing concentration of spermicide and the end-point was taken as the point at which all the peripheral cytoplasm had been removed and only the sperm core of nucleus and tail fibres remained. There were 14 compounds that produced this total effect. All were detergents, of various types, and the effect was purely physical. The most potent compounds caused complete stripping at 0\m=.\5\p=n-\50pmol/cell and most are already used in spermicidal preparations. A further 11 compounds, including sodium hypochlorite and some phenols, caused partial stripping, while 4 compounds caused sperm swelling. The test was not suitable for assessment of metabolic cell poisons. Introduction The methods of assessment and the types of potent spermicides have been reviewed by Bernstein (1974). The usual method of measuring the cytotoxic potencies of compounds against specific cell types is to measure the degree of inhibition of growth, i.e. of cell division. This method cannot be used to assess the potency of spermicides and it has been usual to measure some morphological or biochemical sperm characteristic as the end-point, e.g. the decrease in percentage of motile sperma¬ tozoa after a set time or the time taken for all the spermatozoa to become immotile.